Cargando…

Clinical use of aclidinium in patients with COPD

Chronic obstructive pulmonary disease (COPD) is the sixth-leading cause of death in the US. The Global initiative for Chronic Obstructive Lung Disease (GOLD) guidelines provide evidence-based recommendations for the clinical management of chronic COPD. Long-acting inhaled bronchodilators continue to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reid, Debra J, Carlson, Alexa A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4010633/ https://www.ncbi.nlm.nih.gov/pubmed/24812502 http://dx.doi.org/10.2147/COPD.S40193

Ejemplares similares

New combinations in the treatment of COPD: rationale for aclidinium–formoterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD
por: Suppli Ulrik, Charlotte
Publicado: (2012)

Effects of aclidinium on determinants of COPD severity: symptoms and quality of life
por: Contoli, Marco, et al.
Publicado: (2016)

Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany
por: Rivero-Ferrer, Elena, et al.
Publicado: (2022)

Patient-reported outcomes and considerations in the management of COPD: focus on aclidinium
por: Lopez-Campos, Jose Luis, et al.
Publicado: (2015)

The stats are in: an update on statin use in COPD
por: Carlson, Alexa A, et al.
Publicado: (2015)

Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
por: Blasi, F., et al.
Publicado: (2017)

Aclidinium bromide/formoterol fixed-dose combination therapy for COPD: the evidence to date
por: Moitra, Subhabrata, et al.
Publicado: (2015)

Effects of Adding Tiotropium or Aclidinium as Triple Therapy Using Impulse Oscillometry in COPD
por: Manoharan, Arvind, et al.
Publicado: (2016)

Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison
por: Medic, Goran, et al.
Publicado: (2016)

Aclidinium bromide in fixed-dose combination with formoterol fumarate in the management of COPD: an update on the evidence base
por: D’Urzo, Anthony D., et al.
Publicado: (2019)

ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD
por: Watz, Henrik, et al.
Publicado: (2017)

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
por: Zhong, Jun, et al.
Publicado: (2014)

Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
por: Jones, Paul W
Publicado: (2015)

Erratum to: Is aclidinium alone or combined with a LABA a rational choice for symptomatic COPD patients?
por: Blasi, F., et al.
Publicado: (2017)

Differential Outcomes Following 4 Weeks of Aclidinium/Formoterol in Patients with COPD: A Reanalysis of the ACTIVATE Study
por: Koopman, Maud, et al.
Publicado: (2022)

Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years
por: Karabis, Andreas, et al.
Publicado: (2014)

Cost versus utility of aclidinium bromide 400 µg plus formoterol fumarate dihydrate 12 µg compared to aclidinium bromide 400 µg alone in the management of moderate-to-severe COPD
por: Ramos, Mafalda, et al.
Publicado: (2016)

Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease
por: Sims, Michael W, et al.
Publicado: (2011)

Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-severe COPD in three phase III trials
por: McGarvey, Lorcan, et al.
Publicado: (2016)

Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial
por: Wise, Robert A., et al.
Publicado: (2021)

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis
por: Miravitlles, Marc, et al.
Publicado: (2016)

Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study
por: Monteagudo, Mònica, et al.
Publicado: (2017)

Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
por: D’Urzo, Anthony, et al.
Publicado: (2017)

Specific role of combination aclidinium: formoterol in the treatment of chronic obstructive pulmonary disease
por: Matera, Maria Gabriella, et al.
Publicado: (2016)

The Impact of Exacerbation History on the Safety and Efficacy of Aclidinium in Patients with Chronic Obstructive Pulmonary Disease and Increased Cardiovascular Risk: ASCENT-COPD Trial
por: Wise, Robert A, et al.
Publicado: (2021)

Aclidinium inhibits human lung fibroblast to myofibroblast transition
por: Milara, Javier, et al.
Publicado: (2011)

Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study
por: Singh, Dave, et al.
Publicado: (2014)

Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial
por: Beeh, Kai M, et al.
Publicado: (2014)

Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol
por: Singh, Dave, et al.
Publicado: (2017)

The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies
por: Jones, Paul W., et al.
Publicado: (2016)

Effect of Aclidinium Bromide on Exacerbations in Patients with Moderate-to-Severe COPD: A Pooled Analysis of Five Phase III, Randomized, Placebo-Controlled Studies
por: Wedzicha, Jadwiga A., et al.
Publicado: (2016)

Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis
por: Karabis, Andreas, et al.
Publicado: (2013)

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study
por: D’Urzo, Anthony D, et al.
Publicado: (2014)

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
por: Jones, Paul W, et al.
Publicado: (2011)

Emerging Therapeutic Options for the Management of COPD
por: Reid, Debra J., et al.
Publicado: (2013)

AMPLIFY: a randomized, Phase III study evaluating the efficacy and safety of aclidinium/formoterol vs monocomponents and tiotropium in patients with moderate-to-very severe symptomatic COPD
por: Sethi, Sanjay, et al.
Publicado: (2019)

Clinical benefit of two-times-per-day aclidinium bromide compared with once-a-day tiotropium bromide hydrate in COPD: a multicentre, open-label, randomised study
por: Kamei, Tadashi, et al.
Publicado: (2019)

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
por: Beier, Jutta, et al.
Publicado: (2017)

Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT)
por: Bateman, Eric D., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kmr84ldckek4v9jpv7utfao3hv